will conduct complete human genome sequencing
pilot studies of glioblastoma and melanoma for the Broad Institute
. The company will sequence five genomes from samples provided by the institute.
The first genome sequenced will be a test case that has already been studied extensively by the scientific community. The other four genomes are tumor and matched-pair normals; one pair will be used to study glioblastoma and the other melanoma.